1. Home
  2. MESO vs AIV Comparison

MESO vs AIV Comparison

Compare MESO & AIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MESO
  • AIV
  • Stock Information
  • Founded
  • MESO 2004
  • AIV 1975
  • Country
  • MESO Australia
  • AIV United States
  • Employees
  • MESO N/A
  • AIV N/A
  • Industry
  • MESO Biotechnology: Biological Products (No Diagnostic Substances)
  • AIV Real Estate Investment Trusts
  • Sector
  • MESO Health Care
  • AIV Real Estate
  • Exchange
  • MESO Nasdaq
  • AIV Nasdaq
  • Market Cap
  • MESO 1.4B
  • AIV 1.2B
  • IPO Year
  • MESO N/A
  • AIV 1994
  • Fundamental
  • Price
  • MESO $10.64
  • AIV $7.99
  • Analyst Decision
  • MESO Buy
  • AIV
  • Analyst Count
  • MESO 4
  • AIV 0
  • Target Price
  • MESO $18.00
  • AIV N/A
  • AVG Volume (30 Days)
  • MESO 226.6K
  • AIV 707.1K
  • Earning Date
  • MESO 02-26-2025
  • AIV 05-08-2025
  • Dividend Yield
  • MESO N/A
  • AIV 7.52%
  • EPS Growth
  • MESO N/A
  • AIV N/A
  • EPS
  • MESO N/A
  • AIV N/A
  • Revenue
  • MESO $5,670,000.00
  • AIV $210,828,000.00
  • Revenue This Year
  • MESO $178.09
  • AIV $6.96
  • Revenue Next Year
  • MESO $305.06
  • AIV N/A
  • P/E Ratio
  • MESO N/A
  • AIV N/A
  • Revenue Growth
  • MESO N/A
  • AIV 9.38
  • 52 Week Low
  • MESO $5.78
  • AIV $6.89
  • 52 Week High
  • MESO $22.00
  • AIV $9.49
  • Technical
  • Relative Strength Index (RSI)
  • MESO 40.85
  • AIV 48.96
  • Support Level
  • MESO $10.60
  • AIV $7.77
  • Resistance Level
  • MESO $11.26
  • AIV $8.04
  • Average True Range (ATR)
  • MESO 0.41
  • AIV 0.15
  • MACD
  • MESO -0.06
  • AIV -0.00
  • Stochastic Oscillator
  • MESO 12.00
  • AIV 39.09

About MESO Mesoblast Limited

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

About AIV Apartment Investment and Management Company

Apartment Investment & Management Co is a self-managed real estate investment trust. It is focused on property development, redevelopment and various other value-creating investment strategies, targeting the U.S multifamily market. Its operating segments are Development and Redevelopment; Operating, and Other. Development and Redevelopment segment consists of properties that are under construction or have not achieved stabilization, as well as land held for development. Operating segment includes 20 residential apartment communities with 5,243 apartment homes that have achieved a stabilized level of operations. Other segment includes The Benson Hotel, company's only hotel. Majority of revenue is gained from Operating Segment.

Share on Social Networks: